Zhang W, Bai X, Zhao B, et al
The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases, said Martin Holst Lange, executive vice president for Development at Novo Nordisk
R., Morris, A
However, use these medications sparingly under medical guidance to avoid overcorrection into constipation
Although most studies included several medications, current guidelines recommend selecting GLP1-RAs and SGLT2is on the basis of their clinically proven benefits rather than class alone
A board-certified physician handles each review, typically within about four hours